Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the company’s unique understanding of galectin proteins, which are key mediators of biologic function. The company seeks to leverage extensive scientific and development expertise, as well as established relationships with external sources to achieve cost-effective and efficient development. Galectin is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. For more information, visit the company’s website at www.galectintherapeutics.com